Project Grant R41AI197809
Award Date 7/22/26
Completion Date 6/30/27
Dollars Obligated $307K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Menlo Park, CA 94025, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Impact Proteomics LLC $320,863 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish clinical and technical feasibility of an immunoproteomics diagnostic platform for autoimmune disease detection and monitoring. Impact Proteomics will develop and validate an IP-to-mass spectrometry (IP-to-MS) workflow that leverages a patented PromTag system to separate autoantigens from...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $800,097 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop methods for improving antinuclear antibody (ANA) testing and understanding autoimmune disease progression in ANA-positive individuals. The project leverages epidemiological data, biobank resources, and artificial intelligence technologies to address two key knowledge gaps: the long-term risk of autoimmune...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded Emory University $100,228 on November 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into autoreactive, extrafollicular B cell pathways in a TLR7-driven murine model. The project addresses gaps in understanding the origins of extrafollicular effector B cells and the system-wide and microenvironmental signaling that...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $100,228 on October 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to engineer cell-based sensors for autoimmune disease detection and monitoring. The project, titled "Engineered Cell Sensors for Autoimmune Monitoring," develops synthetic cell receptors using Modular Extracellular Sensor Architecture (MESA) to detect interleukin-23 (IL-23), a...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded The Leland Stanford Junior University $127,926 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize autoreactive B cells and their roles in systemic lupus erythematosus (SLE) pathogenesis using immune organoids. The research investigates how autoreactive B cells transition from a...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $818,300 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop modular degradation systems for extracellular proteins (MODES) as potential therapeutics for antibody-driven autoimmune disorders and heart failure. The research focuses on creating bifunctional small molecules designed to selectively remove disease-causing antibodies from circulation while preserving...
- The National Institute of Allergy and Infectious Diseases awarded Beckman Research Institute of the City of Hope $489,500 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and characterize novel molecular pathways regulating inflammatory responses, with particular focus on non-canonical mir-146a biogenesis and its role in immune homeostasis. The research will characterize post-transcriptional mechanisms controlling mir-146a production,...
- The National Institute of Allergy and Infectious Diseases awarded Abterra Biosciences, Inc. $306,555 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a serum antibody repertoire analysis platform for diagnosing systemic lupus erythematosus. Abterra will develop CDR3-SEQ, a novel technology platform that profiles over 1,000 antibody sequences from serum by analyzing the complementarity determining region 3 (CDRH3), the key domain for...
- The National Institute of Allergy and Infectious Diseases awarded Applied Biomedical Science Institute $976,318 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the molecular mechanisms underlying ultralong complementarity-determining region H3 (CDR H3) antibodies produced by cattle. The project investigates two major objectives. The first examines the atypical V(D)J recombination event that generates ultralong CDR H3 genes, specifically the...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded The University of Texas Southwestern Medical Center $207,500 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the genetic and immunological mechanisms of severe autoimmune hepatitis. The research integrates genomic and proteomic approaches to identify genetic risk factors and protein networks...